A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer

drug protocol number
CLEE011E2301
drug sponsor
Novartis
drug study
LEE011 (Ribociclib)
drug trial site
KKUH
drug status
Ongoing
drug phase